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MBoC | ARTICLE
Effects of anchor structure and glycosylation 
of Fcγ receptor III on ligand binding affinity
ABSTRACT Isoforms of the Fcγ receptor III (FcγRIII or CD16) are cell surface receptors for the 
Fc portion of IgG and important regulators of humoral immune responses. Different ligand 
binding kinetics of FcγRIII isoforms are obtained in three dimensions by surface plasmon reso-
nance and in two dimensions by a micropipette adhesion frequency assay. We show that the 
anchor structure of CD16 isoforms isolated from the cell membrane affects their binding af-
finities in a ligand-specific manner. Changing the receptor anchor structure from full to partial 
to none decreases the ligand binding affinity for human IgG1 (hIgG1) but increases it for mu-
rine IgG2a (mIgG2a). Removing N-glycosylation from the CD16 protein core by tunicamycin 
also increases the ligand binding affinity. Molecular dynamics simulations indicate that degly-
cosylation at Asn-163 of CD16 removes the steric hindrance for the CD16-hIgG1 Fc binding 
and thus increases the binding affinity. These results highlight an unexpected sensitivity of li-
gand binding to the receptor anchor structure and glycosylation and suggest their respective 
roles in controlling allosterically the conformation of the ligand binding pocket of CD16.
INTRODUCTION
In humans, type III cell surface receptors for the Fc portion of im-
munoglobulin (Ig) G (Fcγ receptor III or CD16) are encoded by two 
genes, A and B, which give two protein products, CD16a and 
CD16b, respectively (Kimberly et al., 2002; Nimmerjahn and 
Ravetch, 2008). CD16a is expressed on macrophages, mast cells, 
and natural killer cells as a transmembrane receptor (Ravetch 
and Perussia, 1989; Selvaraj et al., 1989). Expressed exclusively on 
neutrophils, CD16b is the only Fc receptor (FcR) anchored by a gly-
cosyl-phosphatidylinositol (GPI) linker to the plasma membrane 
(Selvaraj et al., 1988). CD16b is polymorphic, with two alleles—neu-
trophil alloantigen 1 (NA1) and 2 (NA2). Despite the lack of a signal-
ing component, CD16b plays an active role in triggering Ca2+ mobi-
lization and neutrophil degranulation (Kimberly et al., 1990; Unkeless 
et al., 1995). Furthermore, in conjunction with FcγRIIa (CD32a), 
CD16b activates phagocytosis, degranulation, and oxidative burst, 
which lead to clearance of opsonized pathogens by neutrophils. 
Moreover, soluble forms of CD16 containing the Ig-like extracellular 
domains of the receptor circulate in plasma (Teillaud et al., 1994).
CD16 are highly glycosylated molecules, with five (CD16a), four 
(CD16bNA1), or six (CD16bNA2) N-glycosylation sites on their extra-
cellular domains (Figure 1). CD16a on NK cells has a higher affinity 
for ligands than on monocytes due to differential cell type–specific 
glycosylation (high mannose– and complex-type oligosaccharides 
for NK cell CD16a but not monocyte CD16a), despite their identi-
cal protein cores (Edberg and Kimberly, 1997). Single-residue re-
placements of the four N-glycosylation sites (Asn-39, Asn-75, Asn-
163, and Asn-170) of CD16bNA1 show that the N163Q mutant 
binds monomeric IgG with higher affinity than the other mutants 
(Drescher et al., 2003). In addition, preincubation of wild-type 
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groups produced the same crystal structure (Sondermann et al., 
2000; Radaev et al., 2001). One group also compared glycosylated 
with aglycosylated CD16bNA2 and showed that they have similar 
binding affinity for human IgG1 (hIgG1; Galon et al., 1997). The 
similarity in three-dimensional (3D) affinity is at odds with the obser-
vation that the glycosylation of CD16 greatly affects its ligand bind-
ing (Edberg and Kimberly, 1997; Drescher et al., 2003).
Ligand binding of CD16 triggers signaling and effector functions 
such as phagocytosis and antibody-dependent cellular cytotoxicity 
(Nagarajan et al., 1995b). Cell surface CD16 binds small immune 
complex in three dimensions and IgG-opsonized surfaces in two di-
mensions (Nagarajan et al., 1995b). Ligand binding kinetics of CD16 
has also been measured in two dimensions by micropipette adhe-
sion assay, which analyzes receptor–ligand interactions across the 
junctional gap between two apposing surfaces (Chesla et al., 1998, 
2000; Williams et al., 2000a,b, 2001; Shashidharamurthy et al., 
2009). This assay can examine effects of membrane organization 
and cellular environment of the interacting molecules that cannot 
be addressed by SPR. The differences between two-dimensional 
(2D) and 3D binding have been highlighted by studies of binding of 
T-cell receptors (TCRs) and coreceptors with peptide-major histo-
compatibility complex (pMHC) molecules (Huang et al., 2010; 
Huppa et al., 2010; Adams et al., 2011; Jiang et al., 2011; Sabatino 
et al., 2011). Indeed, the micropipette assay shows that, compared 
with transmembrane (TM) CD16a (CD16aTM), CD16aGPI binds faster 
and with higher affinity to human and rabbit IgGs but slower and 
with lower affinity to murine IgG2a (mIgG2a; Chesla et al., 2000). 
Previous study suggests that the membrane anchor influences li-
gand binding by conformational change of CD16 (Chesla et al., 
2000).
In the study, we further explored the effect of anchor structure of 
CD16 on its ligand binding using three different methods to gener-
ate soluble CD16s with different anchor structures, allowing us to 
isolate the effect of linker segment from the membrane anchor itself 
on the intrinsic binding parameters. We also tested how glycosyl-
ation of the receptor affected ligand binding, by using tunicamycin 
treatment to block the addition of sugar moieties to the protein 
core. Our results show that affinity of CD16 binding to hIgG1 cor-
relates with receptor anchor structures, and this correlation is in-
verted upon switching ligand from hIgG1 to mIgG2a, suggesting 
that long-range conformational change on the receptor anchor 
could propagate to the ligand binding epitope. Aglycosylated 
CD16 has higher affinity for hIgG1 than the glycosylated forms, sug-
gesting an important role of posttranslational modification in regu-
lating receptor binding affinity. Molecular dynamics (MD) simula-
tions show that deglycosylation of CD16 removes the steric 
hindrance for CD16–hIgG1 binding, resulting in increased binding 
affinity.
RESULTS
Solubilized CD16 captured on microspheres specifically 
binds IgG coated on red blood cells
To test for binding specificity, adhesion frequencies of IgG coated 
on red blood cells (RBCs) to solubilized CD16 of different forms and 
anchor structures (Figure 1) captured by 214.1 precoated on micro-
spheres were compared with several controls. Adhesion frequencies 
were measured with a 2-s contact duration. As exemplified using 
microspheres incubated with various CD16 lysates (Figure 2A), the 
∼50% adhesion frequencies to hIgG1-coated RBCs were reduced to 
∼10% by the anti-CD16 antibody, 3G8. Furthermore, use of micro-
spheres incubated with bovine serum albumin (BSA) instead of 
CD16aTM lysate or RBCs not coated with anything (but undergoing 
CD16bNA1-transfected cells with tunicamycin (an inhibitor of 
N-glycosylation) results in increased binding of monomeric IgG, 
whereas the same treatment of cells transfected with N163Q 
mutant of CD16bNA1 has no effect. These results suggest that 
glycosylation at Asn-163, which is shared by all three CD16 
membrane isoforms and located in the ligand binding pocket 
(Sondermann et al., 2000; Radaev et al., 2001; Ferrara et al., 
2011), regulates the affinity of CD16 for IgG (Drescher et al., 
2003). However, the extent to which the glycosylation affects the 
ligand binding affinity and kinetics has not been quantified. The 
structural basis for the glycosylation effects also has not been 
elucidated.
The cocrystal structures of CD16bNA2 and CD16a in complex 
with an Fc fragment of human IgG1 (hFc1) have been independently 
solved by several groups (Sondermann et al., 2000; Radaev et al., 
2001; Ferrara et al., 2011). Although the crystals obtained have dif-
ferent space group symmetries, the structures are almost identical, 
showing a 1:1 stoichiometry for binding. CD16 adopts the charac-
teristic heart-shaped domain arrangement as described for soluble 
FcγRIIb and other soluble FcRs. Compared with the standalone 
structure, CD16 further opens its interdomain angle by 10° when it 
is liganded with hFc1. Concurrently, hFc1 opens asymmetrically 
upon complex formation, upon which both CH2 domains bend 
away from the C2 axis of the homodimeric hFc1, but one CH2 do-
main is dislocated more than the other.
Ligand binding kinetics of CD16 has been studied using surface 
plasma resonance (SPR; Galon et al., 1997; Maenaka et al., 2001; Li 
et al., 2007). In SPR, one binding partner is immobilized onto a sen-
sor surface over which the other binding partner flows in a fluidic 
phase to interact in three dimensions. Soluble aglycosylated 
CD16NA2 produced by Escherichia coli used in two studies yielded 
drastically different kinetic rates (Galon et al., 1997; Maenaka et al., 
2001), despite the fact that the respective materials from the two 
FIGURE 1: Schematics of solubilized CD16 isoforms with different 
anchor structures and soluble CD16a–Ig chimera. The extracellular 
domains of CD16 are depicted as two Ig-like globules, with the 
N-glycosylation sites shown as sticks. An additional glycan is part of 
the GPI anchor, which acts as a linker between the C-terminus of the 
peptide and the phosphatidylinositol group. The amino acids in 
extracellular domains that differ between CD16a and CD16bNA2 are 
listed. +*The gained glycosylation site in CD16bNA2 due to the change 
D65 → N65.
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was then calculated using the following equation (Williams et al., 
2001):
P P P P= ( – )/(1 – )a t n n  (1)
The Pa versus t binding curve was fitted by Eq. 2 together with the 
separately measured receptor and ligand densities (mr and ml, re-
spectively; Chesla et al., 1998):
P m m A K k t= 1 – exp{– [1 – exp(– )]}a r 1 c a off  (2)
to estimate Ka and koff, the 2D affinity (in μm2) and off-rate (in s−1), 
respectively. The 2D on-rate can be calculated from kon = Kakoff. The 
Ka value is lumped with the contact area Ac in the curve fit, which is 
called collectively the effective 2D affinity. We kept Ac constant in all 
experiments.
CD16aGPI lysate binds hIgG1 with a higher affinity than 
CD16aTM lysate
Previously we showed that CD16aGPI expressed on CHO cells had a 
higher 2D affinity for total human IgG than CHO cell CD16aTM 
(Chesla et al., 2000). This result was confirmed by a new set of mi-
cropipette experiments (Figure 3A). Here we measured binding fre-
quencies at multiple contact durations and then fitted the data to 
Eq. 2 to obtain affinities and off-rates as shown in Figure 2B. We 
showed that the differential 2D affinities observed previously using 
CHO cell CD16 and total human IgG were preserved despite the 
fact that in the new experiments, the CD16a membrane isoforms 
were isolated from the cell surface and captured by 214.1 on the 
microspheres to interact with hIgG1. The higher AcKa values of solu-
bilized than cell surface receptors may partly be due to a higher Ac 
value for the former than the latter because microspheres have a 
smoother surface than CHO cells (Wu et al., 2007), resulting in 
greater effective contact area for the former than the latter. On the 
other hand, CD16aGPI lysate and CD16aTM lysate had comparable 
2D off-rates for dissociation from hIgG1 (Figure 3B), consistent with 
previous findings for cell-surface CD16a membrane isoforms (Chesla 
et al., 2000).
CD16 anchor structure affects 2D binding affinity for hIgG1
The findings that hIgG1 bound with a higher 2D affinity to CD16aGPI 
than CD16aTM even after the receptors were captured from the cell 
lysates on the microspheres (Figure 3A) exclude differential diffusivi-
ties, flexibilities, heights, orientations, and organizations on the 
membrane, as well as any other cell-associated factors between the 
two isoforms, as possible causes for the affinity difference. We 
therefore focused on the structural differences in the membrane an-
chor per se. We hypothesized that the membrane anchor affects li-
gand binding by inducing conformational changes in the ligand 
binding site (Chesla et al., 2000). Because the membrane anchor is 
one Ig domain away from the ligand binding site, the proposed 
anchor effect on binding affinity must be exerted allosterically. Per-
turbing the structure along this allosteric pathway of regulation is 
therefore predicted to alter the binding affinity.
To test this hypothesis, we used lysis, phosphatidylinositol-spe-
cific phospholipase C (PIPLC) treatment, and spontaneous shed-
ding to obtain different anchor structures of solubilized receptors 
from CD16aGPI or CD16bNA2-expressing CHO cells. Lysing the cells 
keeps the molecule’s original GPI anchor. PIPLC treatment enzy-
matically cleaves the diacylglycerol moiety of the GPI anchor. Note 
that PIPLC does not affect N-glycans on CD16. Spontaneous shed-
ding results from the action of metalloproteinases bound to the 
the same CrCl3 procedure except adding IgG) reduced the adhe-
sion frequencies to the background level (∼2%).
The kinetic information is embedded in the curves of adhesion 
frequency versus contact duration, as exemplified by the data in 
Figure 2B, measured with CD16aTM lysate–coated microspheres and 
hIgG1-coated RBCs using seven contact durations, t, from 0.5 to 
16 s. Five microsphere–RBC pairs were tested at each contact dura-
tion, and 100 contacts were repeated for each pair to calculate a 
total adhesion frequency Pt (number of adhesions observed divided 
by the 100 contacts). Nonspecific adhesion frequency, Pn, was con-
trolled using the 214.1-coated microspheres incubated with lysates 
of plain CHO cells (Figure 2B). The specific adhesion frequency Pa 
FIGURE 2: Microspheres bearing CD16 bound RBCs coated with 
hIgG1 specifically. (A) Adhesion frequency of CD16 lysate–coated 
microspheres to hIgG1-coated RBCs was substantially higher than the 
nonspecific adhesions, controlled using a blocking anti-CD16 (3G8) or 
microspheres incubated with BSA (instead of lysates of CD16 
expressing CHO cells) or RBCs not coated with anything. N.D., not 
done. Adhesion frequencies were measured with a 2-s contact 
duration. (B) Adhesion frequency vs. contact duration (t) binding 
curves. The two sets of data (points) were obtained using RBCs 
coated with hIgG1 to contact 214.1-precoated microspheres 
incubated with lysates from CHO cells expressing CD16aTM (filled 
diamonds) or plain CHO cells (open diamonds). For the former, the 
specific adhesion frequency Pa after removing the nonspecific 
adhesion frequency (Eq. 1) is shown and fitted by Eq. 2 (curve). Data 
are mean ± SEM of five RBC-microsphere pairs with 100 contacts each 
per bar or point.
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the full anchor structure plus cytoplasmic tail (lysate) showed a 
much higher affinity for hIgG1 than the molecule with no anchor 
(shedding; Figure 4A left). The PIPLC treatment was not used 
because PIPLC cannot cleave the polypeptide transmem-
brane anchor of CD16aTM. Student’s t test confirmed that the 
affinity differences within each group of CD16 were significant 
(p values in Figure 4A). These results support our hypothesis re-
garding allosteric regulation of ligand binding affinity by recep-
tor anchor.
The anchor effect on ligand binding is inverted when hIgG1 
is replaced by mIgG2a
The correlation between CD16a anchor structure and its affinity was 
inverted when hIgG1 was changed to mIgG2a for all membrane 
isoforms of CD16 (CD16aTM, CD16aGPI, and CD16bNA2), such that 
for each CD16 membrane isoform, the solubilized receptor from ly-
sates with the full anchor structure had the lowest affinity, that from 
shedding with no anchor had the highest affinity, and that cleaved 
from PIPLC treatment (for CD16aGPI and CD16bNA2 only) with partial 
cell membrane, which produces molecules with only the extracel-
lular domain (Lanier et al., 1989). The micropipette adhesion assay 
was applied to measure 2D affinities between hIgG1 and these 
molecules at an 8-s contact duration, long enough for the interac-
tion to reach equilibrium (Figure 2B). Specific adhesion frequen-
cies, Pa, were obtained by removing background adhesion fre-
quencies from total adhesion frequencies using Eq. 1 and then 
substituting into the following equation to calculate the effective 
2D affinities:
A K P m m= – ln(1 – )/c a a r 1  (3)
This equation is a transformation of the equilibrium (i.e., t → ∞) 
version of Eq. 2.
Changing the anchor structure of CD16aGPI from full to partial 
to none resulted in a progressive decrease in its affinity for 
hIgG1 (Figure 4A, middle). The same result was seen with CD-
16bNA2, also a GPI-anchored molecule (Figure 4A, right). Further 
confirmation was obtained using CD16aTM, as the molecule with 
FIGURE 3: Comparison of 2D affinities (A) and off-rates (B) of 
CD16aTM and CD16aGPI for hIgG1. CD16 molecules were expressed 
on CHO cell surface or captured on 214.1-precoated microspheres 
from CHO cell lysates. Data are presented as mean ± SEM from fitting 
Eq. 2 to specific adhesion frequencies measured at multiple contact 
durations (for CD16 on CHO cell surface, six contact durations 
ranging from 0.25 to 8 s, three RBC–CHO cell pairs with 100 contacts 
each per contact duration; for CD16 lysates, seven contact durations 
ranging from 0.5 to 16 s, five RBC–microsphere pairs with 100 
contacts each per contact duration) as in Figure 2B. Data values are 
below the plots; p values from Student’s t test are above the data 
bars.
FIGURE 4: Comparisons of 2D affinities of hIgG1 (A) and mIgG2a (B) 
for CD16. CD16 molecules are captured on 214.1-precoated 
microspheres from CHO cell lysates, supernatants of CHO cells 
treated with PIPLC, or supernatants of CHO cells subjected to 
shedding treatment. Adhesion frequencies were measured with an 8-s 
contact duration and converted to 2D effective affinities using Eq. 3. 
Data are mean ± SEM of 5–15 RBC–microsphere pairs with 100 
contacts each per bar. Data values are below the plots; p values from 
Student’s t test are above data bars.
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To exclude the possibility that the in-
crease of effective 2D affinities of CD16 for 
hIgG1 with tunicamycin treatment was due 
to a cellular effect, we measured 2D binding 
of a soluble CD16a–Ig chimera for hIgG1. In 
agreement with the results of CHO cell 
CD16, the effective 2D binding affinity of 
hIgG1 was fourfold higher for CD16a–Ig se-
creted from CHO cells with tunicamycin 
treatment than without (Figure 5A, far right), 
confirming that the affinity increases in the 
cell-surface CD16 for hIgG1 were due to the 
change in the receptor molecules. The two-
orders-of-magnitude higher effective 2D af-
finities of hIgG1 for soluble CD16a–Ig than 
for CHO cell-surface CD16a, regardless of 
whether they were for glycosylated or degly-
cosylated molecules, are consistent with the 
increase by one to two orders of magnitude 
in effective 2D affinities of hIgG1 for CD16a 
lysates on microspheres (Figure 3A); both 
can be explained by the increases in effec-
tive contact area, Ac. This is consistent with 
our previous report that CD16bNA2 reconsti-
tuted on RBCs has a ∼50-fold-higher effec-
tive 2D affinity for hIgG than the same CD-
16bNA2 reconstituted or transfected on CHO 
cells (Williams et al., 2001).
Finally, we measured 3D affinities of an 
anti-CD16 monoclonal antibody (mAb; 
CLBFcgran-1) for different CD16 isoforms 
using saturation binding experiments and 
Scatchard plot analysis (Figure 5C). Consis-
tently, deglycosylation also increased the 3D 
affinity of CLBFcgran-1 for CD16 (Figure 5D). 
These results support our hypothesis that 
glycosylation perturbs the structure of CD16.
Deglycosylation of CD16 enhances CD16–hFc1 binding
To understand the structural basis for the effects of CD16 glycosyl-
ation on its ligand binding, we performed all-atom, explicit-solvent 
MD simulations for both glycosylated and aglycosylated CD16a li-
ganded with hFc1, which contains two glycans on Asn-297. The start-
ing structure of the simulation of the glycosylated CD16a-hFc1 com-
plex was a crystal structure (Protein Data Bank 3SGJ; Ferrara et al., 
2011) in which two N-glycans are attached to Asn-46 and Asn-163. 
The starting structure of the aglycosylated CD16a-hFc1 complex was 
obtained by removing in silico the glycans of CD16a in the crystal 
structure. After 10 ns in the simulations, the root mean square devia-
tions of the Cα atoms of the complexes reached a plateau, suggest-
ing that the systems were equilibrated (Supplemental Figure S1). The 
40-ns period after equilibration was used for further analysis.
To measure how glycosylation of CD16 affects the binding, we 
calculated the contact times of interaction for residue pairs between 
hFc1 and CD16. Two residues are defined as in contact if any pair of 
their heavy atoms of side chains (Cα atom for glycine) are within 
4.5 Å. Then the contact time is calculated as the fraction of the total 
time that the two residues are in contact. The difference in contact 
time between the aglycosylated and glycosylated complexes is 
shown in Figure 6. Positive or negative value indicates that the inter-
action is strengthened or weakened upon deglycosylation, respec-
tively. Some interactions between the N-terminal loops of hFc1 and 
GPI anchor had intermediate affinity (Figure 4B). Again, Student’s 
t test confirmed the significance of the differences in 2D affinities 
(p values in Figure 4B).
Glycosylation of CD16 molecules affects their ligand 
binding affinities
The effect of the receptor anchor structure on the ligand binding 
affinity may be changed by perturbations in the structure of the li-
gand binding site, as it resides on the other end of the proposed 
allosteric pathway of binding affinity regulation. One possible struc-
ture is the glycan attached to Asn-163 of CD16, which is inside the 
binding pocket of the CD16–hFc1 complex (Sondermann et al., 
2000; Radaev et al., 2001; Ferrara et al., 2011). We thus prepared 
deglycosylated CHO cell CD16 molecules by adding tunicamycin, a 
widely used N-glycosylation inhibitor, to culture medium of CD16-
expressing CHO cells for 40 h. This treatment did not alter CD16 
expression significantly, as revealed by fluorescence-activated cell 
sorting (FACS; unpublished data). The micropipette adhesion fre-
quency assay was used to estimate 2D affinities and off-rates of 
CD16aTM, CD16aGPI, and CD16bNA2 for hIgG1. As expected, for all 
three CD16 isoforms, deglycosylation increased their effective 2D 
affinities for hIgG1 (Figure 5A). By comparison, the 2D off-rates were 
comparable or slightly different between aglycosylated and glyco-
sylated CD16 molecules (Figure 5B).
FIGURE 5: Effects of tunicamycin treatment on CD16–hIgG1 binding. (A) The 2D affinities and 
(B) off-rates of CD16 isoforms expressed on CHO cell-surface and soluble CD16–Ig chimera for 
hIgG1 obtained from fitting Eq. 3 to specific adhesion frequencies measured at six contact 
durations ranging from 0.25 to 8 s (three RBC–CHO cell or RBC–RBC pairs with 50 or 100 
contacts each per contact duration) as in Figure 2B. (C) Representative Scatchard plot analysis 
for saturation binding of CLBFcgran-1 to CD16aTM. (D) The 3D affinities of CD16 isoforms 
expressed on CHO cell surface for CLBFcgran-1 obtained by Scatchard plot analysis as 
illustrated in C. In A, B, and D, data both without and with tunicamycin treatment are presented 
as mean ± SEM. Data values are below the plots; p-values from Student’s t test are above data 
bars.
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another important means for Fc receptors to 
modulate their ligand binding affinities. In 
addition, results from our MD simulations 
suggest a structural basis for deglycosylation 
to increase the ligand binding affinity.
A significant new finding of the present 
work is the preservation of the previously 
observed anchor effect (Chesla et al., 2000) 
after replacement of the CD16-expressing 
CHO cells by solubilized CD16-bearing mi-
crospheres (Figure 3). A concern for using 
solubilized CD16 is that the exposed mem-
brane anchor could induce nonspecific in-
teractions. To test this possibility, we used 
an anti-CD16 antibody, 3G8, to block the 
CD16–IgG binding. The binding was re-
duced by fourfold to fivefold (Figure 2A), 
indicating that the nonspecific binding due 
to exposed anchor is negligible. Also note 
that the same mAb (214.1) was used to cap-
ture different solubilized CD16 molecules, 
therefore presenting the same molecular 
segment to the IgG ligand for binding. In 
spite of this, changing the anchor structure, 
which represents a molecular segment ex-
tending away from the 214.1 capture point 
on the other side of the ligand binding site, 
still affects ligand binding affinity (Figure 4). 
This allows us to rule out the differential dif-
fusivities, flexibilities, heights, orientations, 
and organizations on the membrane, as well 
as any other cell-associated factors of these 
molecules, as possible causes for the ob-
served anchor effects.
Another important new finding is the 
preservation of the ligand specificity of the 
anchor effect, such that the changes of affin-
ity of CD16 for hIgG1 with changes of an-
chor structure are opposite to that for 
mIgG2a: CD16 with full membrane anchor 
has highest affinity for hIgG1 but lowest af-
finity for mIgG2a, whereas CD16 without an-
chor has the lowest affinity for hIgG1 but the 
highest affinity for mIgG2a (Figure 4). The observation further sup-
ports that the anchor effect is caused by CD16 itself rather than its 
cellular environment. To dissect the ligand specificity of the anchor 
effect, we compared the amino acid sequences of hIgG1 and mIgG2a 
(Supplemental Figure S2). The two sequences are highly conserved, 
with >60% identity. However, in the regions directly interacting with 
CD16, three residues are different. As in the CD16–hIgG1 complex 
structure, His-268 and Glu-269 of the hFc1 B chain interact with Lys-
132 of CD16 (Supplemental Figure S3). His-268 and Glu-269 are 
changed to Glu and Asp, respectively, in mIgG2a. This change in-
creases the negative charge of IgG and thus may strengthen the in-
teraction with Lys-132 of CD16. Moreover, Ala-327 of the hFc1 B 
chain is in contact with His-135/136. When Ala-327 is replaced by 
Asp in mIgG2a, additional attractive electrostatic interactions are ex-
pected between Asp-327 and His-135/136. Therefore both changes 
in the binding interface increase interactions between IgG and CD16, 
which may contribute to the higher affinity of mIgG2a for CD16 than 
hIgG1. Note that the CD16 in the complex crystal structure is a solu-
ble form, that is, it does not have an anchor and corresponds to the 
CD16 are weakened (blue spheres in Figure 6C). However, more 
interactions between the CH2 domain of hFc1 and CD16 are 
strengthened (red spheres in Figure 6C). Of interest, the strength-
ened interactions are mostly located near the glycan at Asn-163 of 
CD16 (green sticks in Figure 6C). This result suggests that deglyco-
sylation of CD16 clears the steric hindrance for the CD16–hFc1 
binding.
DISCUSSION
The Fc portions of antibodies can modulate immune responses 
through their interactions with Fc receptors. Different Fc receptors 
have different cell-specific expression patterns, signaling mecha-
nisms, and ligand binding affinities, which enable specific cellular 
functions (Nimmerjahn and Ravetch, 2010). Previously we showed 
that different membrane anchor forms (TM vs. GPI) of the same 
FcγRIII molecule could modulate their ligand binding affinities (Chesla 
et al., 2000). Here we extended this work by showing that the an-
chor structure of CD16 affects the ligand binding affinity even in an 
acellular system. We also demonstrated that glycosylation provides 
FIGURE 6: Deglycosylation of CD16 enhances the CD16-hFc1 binding. (A) Difference in contact 
time between aglycosylated and glycosylated CD16-hFc1 complexes for residue pairs that 
interact between chain A of hFc1 and CD16. Two residues are defined as in contact if any pair of 
their heavy atoms of side chains (Cα atom for glycine) are within 4.5 Å distance. Then the 
contact time is calculated as the fraction of the total time that the two residues are in contact. 
(B) Difference in contact time between aglycosylated and glycosylated CD16-hFc1 complexes 
for residue pairs that interact between chain B of hFc1 and CD16. In A and B, only pairs with 
>0.1 absolute difference are shown. The calculations were done on the last 40 ns of the 
simulations, with one snapshot per 10 ps. (C) Structure of the glycosylated CD16–hFc1 complex 
(PDB 3SGJ). Chains A and B of hFc1 are shown in pink and gray, respectively. CD16 is in green. 
Sticks represent glycans attached to proteins. Red spheres show residues whose interactions 
strengthened upon deglycosylation; blue spheres show residues whose interactions weakened.
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threefold increase in the effective 2D binding affinity. This is consis-
tent with the observation that wild-type CD16bNA1-transfected cells 
treated with tunicamycin exhibit increased binding of monomeric 
IgG (Drescher et al., 2003). Of interest, tunicamycin treatment also 
increases the binding of another Fc receptor, FcαR (CD89), to IgA 
(Xue et al., 2010). It may be a common property that deglycosyl-
ation of FcR causes increased binding of Ig. Of greater interest, de-
glycosylation of one N-glycosylation site among others, Asn-163 of 
CD16 or Asn-58 of CD89, contributes most to the increase of the 
respective binding to IgG or IgA (Drescher et al., 2003; Xue et al., 
2010). In fact, Asn-163 of CD16 and Asn-58 of CD89 are located in 
the binding interfaces of the CD16–IgG (Sondermann et al., 2000; 
Radaev et al., 2001; Ferrara et al., 2011) and CD89–IgA complexes 
(Herr et al., 2003), respectively.
Two previous SPR studies reported similar 3D affinities but drasti-
cally different kinetics for hIgG1 of recombinant aglycosylated solu-
ble CD16bNA2 containing the extracellular region of the receptor 
(Galon et al., 1997; Maenaka et al., 2001). The off-rate measured in 
this work is similar to that found by Maenaka et al. (2001). On the 
other hand, Galon et al. (1997) reported similar 3D affinities for both 
glycosylated and aglycosylated soluble CD16bNA2, contradicting 
our finding that glycosylated and aglycosylated CD16 have different 
2D affinities for hIgG1. This contradiction highlights the intrinsic dif-
ference between 2D and 3D binding, which is also observed in the 
binding between TCR and pMHC ligands (Huang et al., 2010). The 
difference in 2D affinity of CD16 for IgG is only severalfold among 
natural forms of CD16 (TM vs. GPI and glycosylated vs. deglycosyl-
ated), in contrast to several orders of difference in 2D affinity of TCR 
for different pMHC ligands. However, in the physiological situation 
in which CD16 on cell surface binds a large array of IgG on an im-
mune complex, the difference in 2D affinity can be substantially am-
plified to a large difference in 2D avidity. Therefore we believe that 
the difference in 2D affinity of the CD16-IgG binding has a large 
effect on the binding of CD16 to immune complexes. In vivo, the 
change of the CD16–IgG binding affinity by posttranslational modi-
fication of CD16 such as glycosylation may be a way to regulate 
immune responses. In fact, CD16 encoded by the same gene could 
undergo differential cell type–specific glycosylation (Edberg and 
Kimberly, 1997; Drescher et al., 2003), and so the CD16-expressing 
cells may be selectively activated in an immune response. The 
importance of posttranslational processes is also observed in other 
molecular systems, such as CD8, for which nonsialylated glycoforms 
are present in immature thymocytes but virtually absent in mature 
thymocytes. This glycosylation difference is linked to the difference 
in ligand binding affinity between CD8 on mature and immature 
thymocytes (Moody et al., 2003).
Our MD simulations suggest that deglycosylation at Asn-163 of 
CD16 removes the steric hindrance for the CD16–hFc1 binding and 
therefore enhances the binding affinity (Figure 6). This provides a 
structural explanation for the glycosylation effects on the CD16–IgG 
binding shown by us (Figure 5) and others (Drescher et al., 2003).
In summary, we explored the effect of anchor structure and gly-
cosylation of CD16 on ligand binding using three different methods 
to solubilize CD16 molecules with distinct anchor forms. The results 
extended our previous study (Chesla et al., 2000) and showed that 
the membrane anchor structure itself and glycosylation can regulate 
allosterically these intrinsic binding parameters.
MATERIALS AND METHODS
Cells and antibodies
Transfected CHO cells expressing human CD16aTM, CD16aGPI, and 
CD16bNA2, as well as untransfected control CHO cells, were cultured 
shedding form used in our micropipette experiments. We speculate 
that the binding interface is changed through an allosteric mecha-
nism when CD16 has an anchor, and the change depends on the 
anchor form. For the PIPLC-cleaved form of CD16, the interacting 
residues between CD16 and IgG may all be conserved between 
hIgG1 and mIgG2a, so that their affinities for CD16 are similar. How-
ever, for CD16 with a full anchor, other, nonconserved residues may 
interact with CD16, and these interactions are favored for hIgG1, so 
that hIgG1 has higher affinity for CD16 than mIgG2a.
Although our findings may seem surprising, many examples of 
allosteric regulation of ligand binding have been reported. In inter-
actions between selectins and ligands (Lou et al., 2006; Lou and 
Zhu, 2007), between platelet glycoprotein Ibα and von Willebrand 
factor (Yago et al., 2008), and between bacterial FimH receptor and 
mannose ligand (Le Trong et al., 2010), force-induced conforma-
tional changes may give rise to catch bonds (Dembo et al., 1988; 
Marshall et al., 2003). In integrins, allosteric conformational changes 
are related to inside-out and outside-in signaling (Luo et al., 2007) 
and may cause catch bonds (Kong et al., 2009; Chen et al., 2010, 
2012; Xiang et al., 2011). Closer to our findings, the GPI-anchored 
protein Thy-1 has been shown to lose reactivity with several mAbs 
and a polyclonal antibody after anchor cleavage by phospholipase 
C, indicating that the GPI anchor affects the protein conformation 
(Barboni et al., 1995; Kukulansky et al., 1999).
Notwithstanding the foregoing examples, that truncating the 
membrane anchor of a receptor may affect its ligand binding has 
been underappreciated. It is a common practice to make recombi-
nant soluble receptors with membrane anchors truncated and re-
placed by different tags for purification by affinity chromatography. 
Almost all structural determinations of extracellular domains of cell 
surface receptors by crystallography and nuclear magnetic reso-
nance use molecules made in this way. Molecules so made are also 
widely used for kinetics measurements by SPR (Galon et al., 1997; 
Maenaka et al., 2001; Li et al., 2007). It is an implicit but usually un-
tested assumption that the soluble receptors have identical struc-
tures and ligand binding properties as the native molecules on the 
cell membrane. This assumption has been challenged by work re-
vealing drastic differences between 3D kinetics of TCR-pMHC bind-
ing measured by SPR using soluble molecules and 2D kinetics of the 
same interactions measured in situ with cell surface molecules 
(Huang et al., 2010; Huppa et al., 2010; Adams et al., 2011; Jiang 
et al., 2011; Sabatino et al., 2011). The findings of the present work 
also serve as reminder for caution to investigators who use soluble 
molecules for structural and functional studies.
To obtain direct evidence for propagation of conformational 
changes from the membrane anchor to the ligand binding site may 
require structural comparison among CD16 molecules with different 
anchor structures, which are currently not available. We reasoned 
that perturbing the structures that display the conformational 
changes at the ligand binding site might alter the ligand-specific 
binding affinity. We chose the N-glycan attached to Asn-163 of 
CD16, which resides in the binding pocket of the CD16–hFc1 com-
plex (Sondermann et al., 2000; Radaev et al., 2001; Ferrara et al., 
2011). Targeting glycosylation also has interest in its own right be-
cause a substantial number of the recombinant soluble receptors 
used in structure determination and SPR measurements are pro-
duced in aglycosylated forms by E. coli (Sondermann et al., 2000; 
Maenaka et al., 2001; Radaev et al., 2001). It is also an implicit but 
usually untested assumption that the aglycosylated receptors have 
identical structures and ligand binding properties as the native (and 
often glycosylated) molecules on the cell membrane. Using tunica-
mycin to deglycosylate CHO cell CD16 isoforms, we found about 
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(pH 4.5) and resuspended in 120 μl of phosphate buffer. The same 
volume of 2% carbodiimide solution was added dropwise to the 
microsphere suspension, and the mixture was incubated for 3–4 h 
at room temperature with agitation. Unreacted carbodiimide was 
removed by three washes with phosphate buffer and resuspended 
in 200 μl of borate buffer. Next 20–40 μg of 214.1 or 7QD was 
added to the microsphere mixture and incubated overnight at 
room temperature with mixing. Microspheres were collected, and 
the antibody concentration in the supernatant was tested by the 
Micro BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL) to 
estimate the efficiency of coupling. The pellet was resuspended in 
0.2 M borate buffer, and 50 μl of 0.1 M methanolamine was added 
and mixed gently for 30 min at room temperature to block unre-
acted sites on the microspheres. Microspheres were then incu-
bated in 10 mg/ml BSA solution for 30 min at room temperature. 
Finally, microspheres were collected and stored in PBS with 1% 
BSA at 4°C for future use.
Chromium chloride coupling of antibody to RBCs
HIgG1, mIgG2a, or F(ab′)2 of mAb 7QD was covalently coupled to 
the membranes of RBCs using a previously described CrCl3 method 
(Chesla et al., 1998). A 1% CrCl3 solution was prepared, properly 
aged at pH 5, and diluted in 20 mM acetate-buffered saline, pH 5.5, 
at ratios ranging from 1:6700 to 1:17,000. Fresh RBCs were washed 
five times in saline and resuspended to 2% hematocrit. IgG was 
added to each 250-μl sample and mixed. An equal volume of di-
luted CrCl3 solution was added dropwise with constant agitation. 
After 5 min, the reaction was stopped by addition of 0.5 ml PBS/5 
mM EDTA/1% BSA. Cells were subsequently washed and stored in 
EAS45 as described previously (Dumaswala et al., 1996). An aliquot 
from each sample was examined under light microscopy for aggre-
gation. Samples were assayed for coating density and uniformity by 
flow cytometry.
Site-density determination
Site densities of proteins on RBCs (CrCl3-coupled IgG or soluble 
CD16–Ig captured by precoated 7QD) and microspheres (solubi-
lized CD16 captured by precoated 214.1) were determined by 
quantitative fluorescence immunoassay (Chesla et al., 1998, 
2000; Williams et al., 2000a,b, 2001; Shashidharamurthy et al., 
2009). Samples were prepared for flow cytometry as described 
(Chesla et al., 2000). The mean fluorescence intensities of the 
RBCs or microspheres were compared with standard calibration 
beads (Bangs Laboratories, Fishers, IN, and Becton Dickinson, 
San Jose, CA) to determine the mean number of fluorophores 
per cell or microsphere, which was then converted into labeled 
protein per cell.
Micropipette adhesion frequency assay
Two-dimensional affinities and kinetic rates of CD16 for IgG were 
measured by the micropipette adhesion frequency assay as previ-
ously described (Chesla et al., 1998). Briefly, 103 CHO cells express-
ing membrane CD16, microspheres captured with solubilized CD16, 
or RBCs captured with CD16–Ig and 104 ligand-coated RBCs were 
respectively added to separate corners of a cell chamber sufficiently 
far apart to avoid mixing. The cell chamber was filled with RPMI 
(Mediatech, Manassas, VA) plus 1% BSA, 5 mM EDTA, and 0.04% 
sodium azide and mounted on the stage of an inverted microscope 
(Axiovert 100; Zeiss, Oberkochen, Germany). A single CD16-bear-
ing CHO cell, microsphere, or RBC and a single IgG-coated RBC 
were respectively aspirated by two apposing micropipettes and 
aligned via micromanipulation. One pipette was mounted to a 
as described previously (Chesla et al., 1998, 2000). The expressions 
of various forms of CD16s were periodically checked with flow cy-
tometry. The anti-CD16 nonblocking mAb 214.1 (murine IgG1; Fleit 
et al., 1992) was a generous gift from Howard Fleit (State University 
of New York, Stony Brook, NY). The anti-CD16 adhesion blockade 
mAb CLBFcgran-1 and 3G8 were purified from hybridomas (Selvaraj 
et al., 1988). HIgG1 was kindly provided by Adrian Whitty (Biogen, 
Boston, MA) and was purchased from Sigma-Aldrich (St. Louis, MO). 
Fluorescein isothiocyanate–labeled goat anti-human Fc-specific and 
goat anti-mouse Fc-specific antibodies (Sigma-Aldrich) and phyco-
erythrin (PE)-labeled goat anti-human Fc-specific and goat anti-
mouse Fc-specific antibodies (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) were used to estimate the site density of 
hIgG1, CLBFcgran-1, and mIgG2a. The mouse anti-human IgG Fc 
mAb 7QD was purchased from General Bioscience (Brisbane, CA).
Preparation of solubilized CD16 and soluble CD16a–Ig 
chimera
One gram of each CD16-expressing CHO cell pellet was resus-
pended in lysis buffer containing 1% Triton X-100 and protease 
inhibitors and incubated for 30 min at 4°C (Nagarajan et al., 
1995a). Protease inhibitors included the serine protease inhibitors 
phenylmethylsulfonyl fluoride (1 mM) and aprotinin (5 mg/ml) and 
the cysteine protease inhibitor iodoacetamide (1 mM). The lysate 
was clarified by centrifugation at 100,000 × g for 1 h at 4°C. Super-
natant was collected and stored at –80°C for further use. For 
CD16b and CD16aGPI, 1% octyl glucoside was added to lyse the 
cells and preserve the GPI anchor. To prepare PIPLC cleavage of 
GPI-anchored CD16, 107 cells were incubated in 1 ml phosphate-
buffered saline (PBS)/5 mM EDTA, pH 7.4, with 0.2 unit of PIPLC 
for 1 h at 37°C. To prepare shed CD16, 107 CD16-expressing CHO 
cells were incubated in 1 ml of Hanks balanced salt solution at 
37°C for 3 h with gentle mixing. The CD16 molecules so generated 
are schematically shown in Figure 1 in different forms as labeled by 
lysate, PIPLC, and shedding. CD16a–Ig chimera was generated as 
described (Li et al., 2002) and is also depicted in Figure 1. Briefly, 
the chimeric CD16a–Ig cDNA was transfected into CHO cells, 
which were then cultured using CHO serum-free medium. The cul-
ture supernatant was collected, and CD16a-Ig was purified using a 
Sepharose protein G column by affinity chromatography.
Generation of CHO cells expressing aglycosylated CD16
Tunicamycin blocks N-glycosylation synthesis by inhibiting the 
transfer of N-acetylgucosamine-1-phosphate to dolicholmono-
phosphate. At high concentrations, tunicamycin treatment drasti-
cally reduces the expression level of CD16. Twofold serial dilution 
of tunicamycin was performed to determine the optimal concentra-
tion (78 ng/ml) that blocks the glycosylation of CD16 and yet does 
not significantly alter its expression level. CHO cells transfected to 
express cell-surface CD16 or CD16a-Ig were rinsed three times us-
ing culture medium containing 78 ng/ml tunicamycin (Sigma-Al-
drich) and cultured in the same medium for 40 h at 37°C. Cells ex-
pressing CD16 membrane isoforms were then rinsed three times 
with clean culture medium, detached, and analyzed by FACS for 
CD16 expression or by micropipette for IgG binding. Supernatant 
from the CD16a-Ig–expressing cell culture was collected, and 
CD16a–Ig was purified using Sepharose protein G column by affin-
ity chromatography.
Coupling of capturing antibody to microspheres
After being washed twice in carbonate buffer, 10 million carboxyl-
ated microspheres were washed three times in phosphate buffer 
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computer-driven piezoelectric translator to move the two cells into 
contact for a predetermined area and duration. On pipette retrac-
tion, the two cells were either immediately separated (i.e., no adhe-
sion, scored 0) or remained bound, which stretched the RBC for a 
short time before it was detached by force (i.e., adhesion, scored 1). 
This adhesion test cycle was repeated 100 times to estimate adhe-
sion frequency, and three or five pairs of cells were used to obtain a 
mean and SEM of adhesion frequency for each contact duration, 
which was varied from 0.5 to 16 s.
Antibody saturation binding experiment
The affinities of the anti-CD16 mAb CLBFcgran-1 for CD16 isoforms 
expressed on CHO cells were measured by saturation binding with 
twofold serial dilution. CLBFcgran-1 at varying concentrations was 
incubated with CD16-expressing cells for 30 min in triplicate wells 
containing FACS buffer. Cells were then washed and stained with 
PE-conjugated goat anti-mouse Fc specific antibody for an addi-
tional 30 min. Cells were washed, and the expression of CD16 was 
checked via flow cytometry. Controls were performed both with no 
staining and with secondary antibody staining alone without 
CLBFcgran-1.
Molecular dynamics simulation
The starting structure for the glycosylated CD16-hFc1 complex 
was the published cocrystal structure downloaded from the Pro-
tein Data Bank (PDB code 3SGJ; Ferrara et al., 2011). The starting 
structure for the aglycosylated CD16-hFc1 complex was obtained 
by removing in silico the glycans on CD16 in the crystal structure. 
The simulation systems were prepared using LEaP in Amber-
Tools14 (Case et al., 2014). The Amber ff12SB (Maier et al., 2015) 
and GLYCAM06 (Kirschner et al., 2008) force fields were used for 
proteins and glycans, respectively. Each starting structure was 
placed into a truncated octahedral periodic box of TIP3P water 
molecules with a 15-Å minimal distance between the edges of the 
water box and the solute. Sodium and chloride ions were added to 
neutralize the systems and produce a 150 mM ionic strength. MD 
simulations were performed using NAMD (Phillips et al., 2005). 
The particle mesh Ewald method (Darden et al., 1993) was used to 
treat long-range electrostatic interactions. The cutoff for non-
bonded interactions was set to 12 Å, with a switching function 
starting from 10 Å. SHAKE (Ryckaert et al., 1977) was used to con-
strain lengths of bonds involving hydrogen. Time-step was 2 fs. 
The systems were energy minimized using the conjugate gradient 
method in two steps: first with heavy atoms of the proteins fixed, 
and then with heavy atoms of the proteins harmonically restrained 
(force constants of 5 kcal/mol Å2). After minimization, the systems 
were gradually heated from 0 to 310 K during 120-ps canonical 
ensemble (NVT)-MD simulations with harmonic restraints (force 
constants of 5 kcal/mol Å2) on heavy atoms of the proteins. Subse-
quent isothermal isobaric ensemble (NPT)-MD simulations were 
performed for 5 ns with the same harmonic restraints. Then the 
harmonic restraints were reduced to zero in four steps with respec-
tive force constants of 1, 0.1, 0.01, and 0 kcal/mol Å2. Each step 
contains a 1-ns NPT-MD simulation. Finally, NPT-MD production 
simulations were performed for 50 ns each. The simulations were 
run on XSEDE (Towns et al., 2014).
VMD (Humphrey et al., 1996) and PyMOL (version 1.7) were used 
for visualization and analysis. Two residues were defined as in con-
tact if any pair of their heavy atoms of side chains (Cα atom for gly-
cine) were within 4.5 Å. Then the contact time was calculated as 
fraction of total time the two residues were in contact. Only the last 
40 ns was used to calculate contact time.
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